- Heidelberg University
- Dresden University of Technology
- Baxter Healthcare Corporation
Background. There has been much recent interest in accumulation of advanced glycation end-products (AGE) in uraemic patients. Analysis of AGE has been difficult, because commonly used methodologies, i.e. immunodetection assays or fluorescence measurements, reflect group reactivity and are not specific for chemically defined substances. Some investigators measured individual AGE compounds, e.g. pentosidine, carboxymethyllysine, pyrraline or imidazolone, but a systematic assessment of known compounds using specific HPLC methods in diabetic and non-diabetic end-stage renal disease (ESRD) patients during treatment has not been performed.
Methods. For the present study, the concentrations of early and late products of the Maillard reaction in plasma and ultrafiltrate were monitored during high-flux dialysis sessions in diabetic and non-diabetic patients. AGE were analysed by fluorescence spectroscopy and size exclusion chromatography with fluorescence detection. Specific HPLC methods were used to quantify the Amadori product fructoselysine and the AGE compounds pentosidine and pyrraline in acid or enzymatic hydrolysates.
Results, Using size exclusion chromatography, we confirmed a similar fluorescent peak distribution for diabetic and non-diabetic ESRD patients. Main fractions were found at similar to 70, similar to 14 and
Conclusions. High-flux dialysis reduces the plasma concentration of fluorescent AGE compounds, i.e. pentosidine, but the Amadori product fructoselysine is not removed, indicating that this compound is protein associated.
|Number of pages||8|
|Journal||Nephrology Dialysis Transplantation|
|Publication status||Published - Aug 1999|
Sustainable Development Goals
- advanced glycation end-products, diabetes, fluorescence, high-flux haemodialysis, HPLC, Maillard products, pentosidine, MAILLARD REACTION, OXIDATIVE STRESS, RENAL-FAILURE, UREMIA, PENTOSIDINE, PLASMA, SERUM, QUANTIFICATION, HEMODIALYSIS, ENDPRODUCTS